Glenmark gets US nod for alcohol dependence treatment drug

Moneycontrol Bureau

Glenmark Pharmaceuticals' US generic drugs arm has received final abbreviated new drug approval (ANDA) from the US Food and Drugs Administration to launch Acamprosate Calcium delayed release tablets. Its Acamprosate Calcium delayed release tablets are a generic version of Forest Laboratories' Campral delayed release tablets, Mumbai-based Glenmark said. The drug is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence. For the 12-months ending March 2013, Acamprosate garnered sales of USD 21 million in the US market, Glenmark said, citing IMS Health data. The company currently has 88 products authorized for distribution in the US market and 53 ANDAs are pending approval with the drug regulator. Glenmark shares were down 2.1 percent at Rs 558 on NSE in morning trade on Monday.  Also Read: Sun Pharma posts Rs 1,276cr loss in Q1 on Pfizer settlement